The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY DPP-4 Inhibitors, Remicade to Face Market Expansion Re-Pricing in FY2014 Revision
January 23, 2014
-
BUSINESS Azilva Remains No.1 in December “Mind Share” Ranking in GP, HP Markets
January 22, 2014
-
BUSINESS Sales Reps Vied over Questionnaire Transfers in Tasigna Trial, Boss OK’ed Incentive Program: Novartis
January 21, 2014
-
BUSINESS Novartis Sales Reps Transferred Patient Questionnaires in Investigator-Led Trial
January 20, 2014
-
BUSINESS Japan’s First SGLT-2 Inhibitor Suglat Approved: Astellas
January 20, 2014
-
REGULATORY More Manpower, Knowledge Necessary for Giving New Drugs World’s First Approval: PMDA Chief Executive
January 17, 2014
-
REGULATORY Varicella, Adult Pneumococcal Vaccines to Join Japan’s Routine Immunization Program in October
January 16, 2014
-
ORGANIZATION Generic Makers Likely to Disclose Payments to Medical Institutions from Early May
January 15, 2014
-
ORGANIZATION JPWA Chair Weighs Cartel Deal to Unify Tax Display Methods after Sales Levy Hike
January 14, 2014
-
REGULATORY Did Novartis Employees “Willfully” Use Rigged Data in Diovan Ads? Statute of Limitations Will Pose Hurdles to Chase Key Figure
January 10, 2014
-
ORGANIZATION Next Drug Price Revision Won’t Help Promote Generic Use, JGA President Says
January 9, 2014
-
REGULATORY MHLW Files Criminal Complaint against Novartis over Diovan Ads
January 9, 2014
-
BUSINESS Former Pfizer EPBU Head Matsumori Joins SBI Biotech as President
January 8, 2014
-
REGULATORY MHLW to File Criminal Complaint against Novartis Jan. 8
January 8, 2014
-
REGULATORY MHLW Economic Affairs Official Says Shakeout in Generic Sphere “Inevitable”
January 7, 2014
-
BUSINESS New Price Cut Rule for Long-Listed Products Blow to Drug Makers
January 6, 2014
-
ORGANIZATION New Price Cut for Long-Listed Products “Harsh,” Needs Follow-Up Review: FPMAJ Chair Naito
January 1, 2014
-
BUSINESS Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
-
BUSINESS Nissan Chemical Sues Seven Generic Companies over Livalo Patents
December 27, 2013
-
REGULATORY Chuikyo Approves Outline for NHI Price Reform Including New Rule for Long-Listed Drugs; Trial of Premium for New Drug Development to Continue
December 26, 2013
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…